Market research
GENX.V Genix Pharmaceuticals Corporation
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.48
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA37232A1093
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.48
About
About Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GENX.V discussion.
5 years, 5 months ago
Genix Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 9.7% above its 200 day moving average.
From a valuation standpoint, the stock is 462.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5737.4.
Genix Pharmaceuticals Corporation's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1390.7% to $-563K since the same quarter in the previous year.
Finally, its free cash flow fell by 263.2% to $-165K since the same quarter in the previous year.
Based on the above factors, Genix Pharmaceuticals Corporation gets an overall score of 1/5.